• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Oculis Announces Presentation of Phase 2 ACUITY trial results with Privosegtor in Acute Optic Neuritis at ECTRIMS

    9/22/25 4:00:00 AM ET
    $OCS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $OCS alert in real time by email

    ZUG, Switzerland, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS) ("Oculis"), a global biopharmaceutical company focused on innovations for ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced the upcoming presentation of the positive Phase 2 ACUITY trial results investigating Privosegtor (OCS-05) in acute optic neuritis at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2025 Congress.

    Details of Oculis' presentation:

    ECTRIMS 2025:

    • Reduction in Retinal Ganglion Cell Loss and Improved Low Contrast Visual Acuity with Privosegtor in Acute Optic Neuritis: Results from a Multicenter Randomized Placebo-Controlled Double-Masked Trial.

      Presenter: Céline Louapre, M.D., Ph.D., Pitié-Salpêtrière Hospital

      Session: Late Breaking Abstracts

      Date/Time: Wednesday, September 24, 2025; 08:30 CET



    Riad Sherif, M.D., Chief Executive Officer of Oculis, commented: "It is a privilege to collaborate with Pitié-Salpêtrière Hospital, a world-renowned center for modern neurology, on the Phase 2 ACUITY trial investigating Privosegtor (OCS-05) in patients with acute optic neuritis, a well-established clinical model for neuroprotection. Topline results showed clinically meaningful improvements in vision with 18 letters at 3 months, along with the preservation of retinal structure and a favorable safety profile, highlighting Privosegtor's potential broad applicability in various neuro-ophthalmic and neurological diseases. We look forward to sharing these significant results with the multiple sclerosis community as we continue to advance this candidate into further studies in optic neuritis and beyond, including a new program to be initiated for the treatment of MS relapses."

    Céline Louapre, M.D., Ph.D., added: "It is an honor to present these positive results at ECTRIMS, the largest MS congress in the world. In this study, Privosegtor (OCS-05) demonstrated promising neuroprotective effects, including the preservation of retinal ganglion cells, and was also associated with significant improvements in low contrast visual acuity. With acute optic neuritis often manifesting as the first sign of multiple sclerosis or as a frequent MS relapse type, these results highlight the potential of this neuroprotective candidate to transform outcomes for patients experiencing acute relapses of this autoimmune disease."

    Céline Louapre, M.D., Ph.D., is the Head of Neuroscience Clinical Investigation Center at the Paris Brain Institute, Pitié-Salpêtrière Hospital, where more than 80 clinical trials are currently conducted in the field of neuroscience. As a clinical neurologist with a Ph.D. in neuroscience, she is particularly interested in bringing new MRI technical developments to study the pathophysiologic mechanisms of MS, and in developing translational clinical research to foster remyelination and neuroprotection. She also serves as the Medical Coordinator of the National Multiple Sclerosis Clinical Research Network, FCRIN4MS, and as a Professor of Neurology at Sorbonne University, Pitié-Salpêtrière Hospital.

    About Privosegtor (OCS-05)

    Privosegtor is a novel peptoid small molecule candidate with the potential to become a neuroprotective therapy for optic neuritis and other neuro-ophthalmic diseases. The recent positive topline results from the ACUITY Phase 2 trial showed Privosegtor (OCS-05)'s neuroprotective benefits, including anatomical preservation of the retina and improvements in visual function, in patients suffering from acute optic neuritis. Consistent results were observed in animal models of neuroinflammation and neurodegeneration where Privosegtor showed preservation of retinal ganglion cell damage and was associated with improvements in mobility (clinical function disability). Privosegtor has received orphan drug designation from both the FDA and the EMA for acute optic neuritis. In addition to this indication, a neuroprotective treatment could potentially have wide applicability in neuro-ophthalmic and neurology indications.

    Privosegtor is an investigational drug in Phase 2 and has not received regulatory approval for commercial use in any country.

    About Acute Optic Neuritis

    Acute optic neuritis is a rare condition characterized by acute inflammation of the optic nerve, which can lead to permanent visual impairment. It affects up to 8 in 100,000 people worldwide and often represents the first sign of multiple sclerosis1. It mainly occurs in adults between the ages of 20 and 40 years and is more frequent in women (2:1)2. The acute inflammatory process of acute optic neuritis results in the loss of myelin covering the optic nerve and its axons. Initially, patients often experience ocular pain that worsens with eye movement, and vision loss. Once the inflammation recedes, remyelination usually occurs but it is incomplete. Without the myelin sheath protecting the axon, neurons located in demyelinated segments become fragile and prone to death, as early as the first weeks following symptoms onset. Unfortunately, damaged axons cannot regrow, leading to permanent visual impairment. To date there is no neuroprotective therapy approved for acute optic neuritis and unmet needs remain for medicines that can prevent vision loss after an acute episode of optic neuritis.

    About Oculis

    Oculis is a global biopharmaceutical company (NASDAQ:OCS, XICE: OCS)) focused on innovations addressing ophthalmic and neuro-ophthalmic conditions with significant unmet medical needs. Oculis' highly differentiated late-stage clinical pipeline includes three core product candidates: OCS-01, an eye drop in pivotal registration studies, aiming to become the first non-invasive topical treatment for diabetic macular edema; Privosegtor (OCS-05), a neuroprotective candidate in Phase 2 for acute optic neuritis, with potentially broad clinical applications in various neuro-ophthalmic and neurological diseases; and Licaminlimab (OCS-02), a novel, topical anti-TNFα in Phase 2, being developed with a genotype-based approach to drive personalized medicine in dry eye disease. Headquartered in Switzerland with operations in the U.S. and Iceland, Oculis is led by an experienced management team with a successful track record and supported by leading international healthcare investors.

    For more information, please visit: www.oculis.com

    (1)Martínez-Lapiscina EH, et al. (2014): Is the incidence of optic neuritis rising? Evidence from an epidemiological study in Barcelona (Spain) 2008-2012. J Neurol. 2014 Apr; 261(4): 759-767.
    (2)Pérez-Cambrodí RJ, Gómez-Hurtado Cubillana A, Merino-Suárez ML, Piñero-Llorens DP, Laria-Ochaita C. Optic neuritis in pediatric population: a review in current tendencies of diagnosis and management. J Optom. 2014 Jul-Sep;7(3):125-30. 
      

    Cautionary Statement Regarding Forward-Looking Statements

    This press release contains forward-looking statements and information. For example, statements regarding the potential benefits of Privosegtor (OCS-05), including patient impact and market opportunity; the potential of Privosegtor (OCS-05) to become a first-in-class neuroprotective therapy for acute optic neuritis and other neuro-ophthalmic diseases; the initiation, timing, progress and results of Oculis' clinical trials; Oculis' research and development programs, regulatory and business strategy and future development plans; and Oculis' ability to advance product candidates into, and successfully complete, clinical trials, are forward-looking. All forward-looking statements are based on estimates and assumptions that, while considered reasonable by Oculis and its management, are inherently uncertain and are inherently subject to risks, variability, and contingencies, many of which are beyond Oculis' control. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, assurance, prediction or definitive statement of a fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. All forward-looking statements are subject to risks, uncertainties and other factors that may cause actual results to differ materially from those that we expected and/or those expressed or implied by such forward-looking statements. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of Oculis, including those set forth in the Risk Factors section of Oculis' annual report on Form 20-F and other documents filed with the U.S. Securities and Exchange Commission (the "SEC"). Copies of these documents are available on the SEC's website, www.sec.gov. Oculis undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

    Oculis Contacts

    Ms. Sylvia Cheung, CFO

    [email protected]

    Investor Relations

    LifeSci Advisors

    Corey Davis, Ph.D.

    [email protected]

    Media Relations

    ICR Healthcare

    Amber Fennell / David Daley / Sean Leous

    [email protected]



    Primary Logo

    Get the next $OCS alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $OCS

    DatePrice TargetRatingAnalyst
    8/27/2025$36.00Buy
    Needham
    12/5/2023$30.00Buy
    Chardan Capital Markets
    10/5/2023$35.00Buy
    Stifel
    6/14/2023$22.00Buy
    BofA Securities
    6/12/2023$28.00Buy
    H.C. Wainwright
    6/8/2023$58.00Outperform
    Robert W. Baird
    5/10/2023$23.00Buy
    Pareto
    4/28/2023$27.00Outperform
    Wedbush
    More analyst ratings

    $OCS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Needham initiated coverage on Oculis Holding AG with a new price target

    Needham initiated coverage of Oculis Holding AG with a rating of Buy and set a new price target of $36.00

    8/27/25 8:25:52 AM ET
    $OCS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chardan Capital Markets initiated coverage on Oculis Holding AG with a new price target

    Chardan Capital Markets initiated coverage of Oculis Holding AG with a rating of Buy and set a new price target of $30.00

    12/5/23 8:03:01 AM ET
    $OCS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Stifel initiated coverage on Oculis Holding AG with a new price target

    Stifel initiated coverage of Oculis Holding AG with a rating of Buy and set a new price target of $35.00

    10/5/23 7:50:21 AM ET
    $OCS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OCS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Oculis Announces Presentation of Phase 2 ACUITY trial results with Privosegtor in Acute Optic Neuritis at ECTRIMS

    ZUG, Switzerland, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS) ("Oculis"), a global biopharmaceutical company focused on innovations for ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced the upcoming presentation of the positive Phase 2 ACUITY trial results investigating Privosegtor (OCS-05) in acute optic neuritis at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2025 Congress. Details of Oculis' presentation: ECTRIMS 2025: Reduction in Retinal Ganglion Cell Loss and Improved Low Contrast Visual Acuity with Privosegtor in Acute Optic Neuritis: Results from a Multicenter Randomized

    9/22/25 4:00:00 AM ET
    $OCS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oculis and EURETINA Announce the Winner of the Ramin Tadayoni Award 2025

    ZUG, Switzerland, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS) ("Oculis"), a global biopharmaceutical company focused on innovations for ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced, in collaboration with EURETINA, the winner of the Ramin Tadayoni Award 2025. The Ramin Tadayoni Award honors the next generation of ophthalmologists by supporting an exceptional postgraduate scholar in retina research. It was established in 2024 in memory of the late Professor Ramin Tadayoni, Oculis' former Chief Scientific Officer and a globally renowned leader in retinal science. This year's award recognizes Prithvi Ramtohul

    9/4/25 1:00:00 PM ET
    $OCS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oculis to Present Clinical Trial Results in Diabetic Macular Edema and Acute Optic Neuritis at Ophthalmology Conferences

    Phase 2 ACUITY trial results for Privosegtor (OCS-05) in acute optic neuritis to be presented in EURETINA late-breaking session Expanded data analysis from Phase 3 Stage 1 DIAMOND program for OCS-01 eye drops in diabetic macular edema (DME) to be presented ZUG, Switzerland, Sept. 01, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS) ("Oculis"), a global biopharmaceutical company focused on innovations for ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced upcoming presentations at the Ophthalmology Futures Retina Forum, the EURETINA Innovation Spotlight (EIS), the 25th European Society of Retina Specialists (EURETINA) Congress, and the Re

    9/1/25 4:00:00 AM ET
    $OCS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OCS
    SEC Filings

    View All

    SEC Form 6-K filed by Oculis Holding AG

    6-K - Oculis Holding AG (0001953530) (Filer)

    8/21/25 4:30:21 PM ET
    $OCS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Oculis Holding AG

    6-K - Oculis Holding AG (0001953530) (Filer)

    8/1/25 4:05:10 PM ET
    $OCS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by Oculis Holding AG

    S-8 - Oculis Holding AG (0001953530) (Filer)

    6/5/25 4:38:25 PM ET
    $OCS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OCS
    Financials

    Live finance-specific insights

    View All

    Oculis Announces Positive Top Line Results from DIAMOND Stage 1 Phase 3 Trial in Diabetic Macular Edema with OCS-01 Eye Drops

    DIAMOND trial in Diabetic Macular Edema (DME) with topical OCS-01 met its stage 1 objective of validating the loading and maintenance dosing regimen designed to optimize OCS-01 efficacy potential with robust statistical significancePrimary efficacy endpoint of mean change in Best Corrected Visual Acuity (BCVA) versus baseline at Week 6 showed statistically significant increase in visual acuity in the OCS-01 arm compared to vehicle armStatistically significant secondary endpoints showed higher percentage of patients achieving ≥15-letter improvement in BCVA and better improvement in retinal thickness in the OCS-01 arm versus vehicle armOCS-01 was well-tolerated with no unexpected adverse event

    5/22/23 6:30:00 AM ET
    $OCS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oculis to Host Conference Call on April 13, 2023 to Discuss Late-Stage Pipeline and Near-Term Clinical Milestones

    ZUG, Switzerland and BOSTON, April 04, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS) ("Oculis"), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announces that it will host a virtual conference call and webcast to present an overview of its late-stage pipeline and discuss expected near-term clinical milestones on Thursday, April 13 from 8:00am-9:00am ET / 13:00-14:00 BST / 14:00-15:00 CET. Oculis is focused on becoming a leading global ophthalmic biopharmaceutical company with product candidates to address areas of significant medical needs, including diabetic macular edema (DME), dry eye disease (DED), and neuro-retina indica

    4/4/23 7:00:00 AM ET
    $OCS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OCS
    Leadership Updates

    Live Leadership Updates

    View All

    Oculis Appoints Mark Kupersmith, M.D., and Sebastian Wolf, M.D., Ph.D., World-Renowned Neuro-Ophthalmology and Retina Experts, as Chief Medical Advisors

    Mark Kupersmith, M.D. appointed as Chief Medical Advisor, Neuro-Ophthalmology, following positive Phase 2 ACUITY trial results with Privosegtor (OCS-05) in acute optic neuritis and initiation of multiple programs in neuro-ophthalmologySebastian Wolf, M.D., Ph.D. appointed as Chief Medical Advisor, Ophthalmology, following the material advancement in retina programs with recent enrollment completion of Phase 3 DIAMOND trials of OCS-01 eye drops in diabetic macular edema and positive Phase 2 ACUITY trial results with Privosegtor (OCS-05) in acute optic neuritis ZUG, Switzerland, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS) ("Oculis"), a global biopharmaceutical company f

    8/25/25 4:00:00 AM ET
    $OCS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oculis Publishes Invitation to the Annual General Meeting

    ZUG, Switzerland, May 09, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS) ("Oculis"), today published the invitation to the 2025 Annual General Meeting, which will be held on June 4, 2025 at Ochsen-Zug, Kolinplatz 11, CH-6300 Zug, Switzerland, at 3:00 p.m. CEST / 9:00 a.m. EDT. The 2025 Annual General Meeting will be held in-person and broadcast. To join the broadcast, please use the following link. Information pertaining to the 2025 Annual General Meeting, including meeting materials, can be accessed on the Oculis website here. Oculis will host a virtual information session for all shareholders on May 19, 2025 from 4:00 to 5:00 p.m. CEST / 10:00 to 11:00 a.m. EDT, during

    5/9/25 4:05:00 PM ET
    $OCS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Virometix appoints Christina Ackermann as Chair and Tim Ramdeen as member of the Board

    Virometix AG, a privately held Swiss biotechnology company developing a new generation of fully synthetic vaccines to generate targeted and protective immune responses against infectious diseases and cancer today announces the appointment of Christina Ackermann as Chairwoman and Tim Ramdeen as a new member of its Board of Directors. Ms. Ackermann brings over 27 years of legal and management experience within the healthcare industries. Mr. Ramdeen has nearly a decade of experience in private equity, hedge fund investing, and capital markets. Christina Ackermann and Tim Ramdeen have led clinical and commercial companies through product development, growth, and commercialization while raising

    10/8/24 5:00:00 AM ET
    $ENTO
    $OCS
    $ONCO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OCS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Oculis Holding AG

    SC 13G - Oculis Holding AG (0001953530) (Subject)

    12/9/24 9:43:55 PM ET
    $OCS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Oculis Holding AG

    SC 13G/A - Oculis Holding AG (0001953530) (Subject)

    11/7/24 4:15:49 PM ET
    $OCS
    Biotechnology: Pharmaceutical Preparations
    Health Care